OncLive TV

Andrew P. Jallouk, BS, MD, PhD, discusses research assessing post-transplant relapse prevention strategies in patients with hematologic malignancies.

Naval G. Daver, MD, discusses the future of targeted therapy development for patients with acute myeloid leukemia.

Elias Jabbour, MD, discusses outcomes from the phase 3 PhALLCON trial in patients with Ph-positive acute lymphoblastic leukemia.

Debu Tripathy, MD, discusses the current state of the HER2-positive breast cancer treatment paradigm.

Sunil Iyer, MD, discusses the design of the phase 3 COMMANDS trial in patients with lower-risk myelodysplastic syndrome with anemia.

Zeynep Eroglu, MD, discusses a phase 1/2 trial that evaluated ceritinib alone and in combination with trametinib in patients with mutant melanoma.

Zeynep Eroglu, MD, discusses the efficacy and safety of ceritinib as monotherapy and in combination with trametinib in pretreated advanced melanoma.

Yang Yang Hartwich, PhD discusses a study delving into the mechanisms underlying chemoresistance in ovarian cancer.

Manmeet Singh Ahluwalia, MD, MBA, FASCO, discusses how advancements in precision medicine have improved outcomes for patients with brain metastases.

John Paul Diaz, MD, discusses the evolving use of precision medicine approaches in cervical cancer management.

Scott Kopetz, MD, PhD, FACP, discusses the potential FDA approval of adagrasib in combination with cetuximab in KRAS G12C-mutatated colorectal cancer.

Gottfried Konecny, MD, discusses the importance of evaluating PROs in patients with platinum-resistant ovarian cancer receiving mirvetuximab soravtansine.

Akriti Jain, MD, discusses the phase 1b VERONA study of venetoclax plus azacitidine in higher-risk myelodysplastic syndromes.

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Rita Nanda, MD, discusses the importance of testing for HER2-low status in patients with early-stage breast cancer.

Kenneth C. Anderson, MD, discusses the recent FDA ODAC decision regarding the use of cilta-cel in relapsed/refractory multiple myeloma.

Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Lauren E. Nye, MD, discusses future directions for the treatment of patients with HER2-positive breast cancer with brain metastases.

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.